Subcorneal Pustular Dermatosis Treated with PUVA Therapy

Bauwens, Matthias; Coninck, A. De; Roseeuw, Diane

doi:10.1159/000018113

Cited by 27 publications

(12 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Variable results have been reported with oral retinoids 166, 167 . Broad and narrow band UVB, PUVA and re-PUVA have been reported to be successful in the management of SCPD, although PUVA was found ineffective in one case 124, 159, 168–170 . Recalcitrant disease has been managed successfully with infliximab 171, 172 .…”

Section: Pustular Psoriasis and Clinical Variantsmentioning

confidence: 96%

Autoinflammatory Pustular Neutrophilic Diseases

Naik

Cowen

2013

Dermatologic Clinics

114

View full text Add to dashboard Cite

SYNOPSIS The inflammatory pustular dermatoses constitute a spectrum of non-infectious conditions ranging from localized involvement to generalized disease with associated acute systemic inflammation and multi-organ involvement. Despite the variability in extent and severity of cutaneous presentation, each of these diseases is characterized by non-infectious neutrophilic intra-epidermal microabscesses. Many share systemic findings including fever, elevated inflammatory markers, inflammatory bowel disease and/or osteoarticular involvement, suggesting potential common pathogenic links (Figure 1). The recent discoveries of several genes responsible for heritable pustular diseases have revealed a distinct link between pustular skin disease and regulation of innate immunity. These genetic advances have led to a deeper exploration of common pathways in pustular skin disease and offer the potential for a new era of biologic therapy which targets these shared pathways. This chapter provides a new categorization of inflammatory pustular dermatoses in the context of recent genetic and biologic insights. We will discuss recently-described monogenic diseases with pustular phenotypes, including deficiency of IL-1 receptor antagonist (DIRA), deficiency of the IL-36 receptor antagonist (DITRA), CARD14-associated pustular psoriasis (CAMPS), and pyogenic arthritis, pyoderma gangrenosum, acne (PAPA). We will then discuss how these new genetic advancements may inform how we view previously described pustular diseases, including pustular psoriasis and its clinical variants, with a focus on historical classification by clinical phenotype.

show abstract

Section: Pustular Psoriasis and Clinical Variantsmentioning

confidence: 96%

Autoinflammatory Pustular Neutrophilic Diseases

Naik

Cowen

2013

Dermatologic Clinics

114

View full text Add to dashboard Cite

show abstract

“…Psoralen plus ultraviolet (UV) light therapy (PUVA) alone or with either dapsone or a retinoid has been used with good results [73,75,76]. Successful cases controlled with UVB alone or with minocycline have also been reported [77,78].…”

Section: Managementmentioning

confidence: 99%

“…Additionally, sorafenib, which caused SPD in one case, has reportedly induced psoriasiform eruptions, two of which were pustular in nature [90,91]. [76] Clinical and histologic characteristics that differ between annular pustular psoriasis and SPD cannot be ignored. The hypopyon nature of the pustules in SPD, which has not been described in pustular psoriasis, is one.…”

Section: Reappraisalmentioning

confidence: 99%

Subcorneal Pustular Dermatosis: A Review of 30 Years of Progress

2016

View full text Add to dashboard Cite

Subcorneal pustular dermatosis (SPD), also known as Sneddon-Wilkinson disease, is a rare, benign yet relapsing pustular dermatosis. Its incidence and prevalence have not been well studied. It characteristically presents as hypopyon pustules on the trunk and intertriginous areas of the body. SPD is similar to two other disease entities. Both SPD-type immunoglobulin (Ig)-A pemphigus and annular pustular psoriasis clinically and histologically present similarly to SPD. Immunologic studies separate SPD-type IgA pemphigus from SPD and pustular psoriasis. However, there is still an unclear designation as to whether SPD is its own entity distinct from pustular psoriasis, as the once thought characteristic histologic picture of psoriasis does not hold true for pustular psoriasis. SPD has been reported to occur in association with several neoplastic, immunologic, and inflammatory conditions. Dapsone remains the first-line treatment for SPD, although dapsone-resistant cases have been increasingly reported. Other therapies have been used singly or as adjunctive therapy with success, such as corticosteroids, immunosuppressive agents, tumor necrosis factor inhibitors, and ultraviolet light therapy. This article provides a review of the last 30 years of available literature, with a focus on successful treatment options and a suggestion for reappraisal of the classification of SPD.

show abstract

“…Subcorneal pustular dermatosis (SPD) is a rare, chronic, benign and relapsing pustular eruption of unknown aetiology and pathogenesis 1 . Although many therapeutic agents have been proposed, few resistant or intolerant patients have been reported 1,3–9 …”

Section: Comparison Of Spd Cases Treated With Cyclosporin a In The LImentioning

confidence: 99%

“…Dapsone (50–200 mg/day), the main agent in SPD, inhibits the cytotoxic effects of peripheral neutrophils and may, as sulphapyridines, cause life‐threatening side‐effects including methaemoglobinaemia and haemolytic anaemia 1 . Corticosteroids, tacalcitol, etretinate, PUVA, acitretin, mebhydroline, ketoconazole, colchicine, mizoribine, minocycline, vitamine E, niacin and, recently, infliximab have also been proposed 1,3–9 …”

Section: Comparison Of Spd Cases Treated With Cyclosporin a In The LImentioning

confidence: 99%